That $930M drug Alexion bought to pair with Soliris, Ultomiris? AstraZeneca says it just aced a PhIII test
Back in 2019, Alexion paid $930 million to snap up Achillion and danicopan, its promising companion drug to Soliris. Three years later, Alexion itself became …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
